ARTICLE | Clinical News
Dementia-related psychosis data could make Acadia’s pimavanserin a blockbuster
December 5, 2019 11:55 PM UTC
Updated on Dec 6, 2019 at 12:32 AM UTC
Pivotal data reported late Wednesday support Acadia’s bid for a label expansion that would bring pimavanserin to the broader population of dementia-related psychosis and help allay safety concerns associated with a black box on the drug’s label.
Shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $6.20 (14%) to $50.48 Thursday, adding more than $950 million to the company’s market cap...
BCIQ Company Profiles